Crestor vs Amlodipine: Combining the Two (Rationale + Risk)

Why Comparing Crestor and Amlodipine Is the Wrong Question

Rosuvastatin and amlodipine are not interchangeable. They operate on completely different physiological systems, so asking which one is better is a bit like asking whether a seatbelt is better than an airbag. Most cardiologists would say: use both.

Rosuvastatin works by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The downstream effect is a dose-dependent fall in LDL-C, a modest rise in HDL-C, and reductions in high-sensitivity C-reactive protein (hsCRP). Amlodipine, by contrast, blocks L-type voltage-gated calcium channels in vascular smooth muscle, causing arteriolar vasodilation, reduced systemic vascular resistance, and lower blood pressure.

The Two Independent Risk Axes

Atherosclerotic cardiovascular disease (ASCVD) risk is driven by at least two separate, additive axes. Dyslipidemia accelerates plaque formation and vulnerability. Hypertension accelerates endothelial injury, plaque rupture, and left ventricular hypertrophy. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states directly: "Statin therapy is the first-line treatment for primary prevention of ASCVD in patients with elevated LDL-C... And blood pressure control with antihypertensive therapy provides additional, independent risk reduction." [1]

Treating only one axis while ignoring the other leaves a large residual risk on the table. A patient on rosuvastatin 20 mg with an LDL-C of 68 mg/dL but an uncontrolled blood pressure of 158/96 mmHg still faces roughly double the 10-year ASCVD risk of a matched patient whose blood pressure is controlled.

What Each Drug Actually Does to Outcomes

In JUPITER (N=17,802), rosuvastatin 20 mg reduced the primary composite endpoint of major cardiovascular events by 44% versus placebo (hazard ratio 0.56; 95% CI 0.46 to 0.69; P<0.00001) in patients with elevated hsCRP but LDL-C below 130 mg/dL [2]. In ASCOT-BPLA (N=19,257), the amlodipine-based regimen reduced the primary endpoint of non-fatal MI plus fatal coronary heart disease by 10% versus an atenolol-based regimen, with a 23% reduction in stroke (P<0.0003) [3]. These trials measured different comparators, different patient populations, and different endpoints. Placing them side-by-side to ask "which is better" misreads what both trials were designed to answer.

The Combination Rationale: Why Many Patients Need Both

The case for co-prescribing rosuvastatin and amlodipine is grounded in additive risk-factor control, not combination between the drugs themselves. Patients with stage 1 or stage 2 hypertension plus elevated LDL-C or a 10-year ASCVD risk above 7.5% routinely meet guideline thresholds for both drug classes simultaneously.

ASCOT-LLA: The Closest Thing to a Combination Trial

The ASCOT-LLA sub-study randomized 10,305 hypertensive patients (many already on amlodipine-based therapy) to atorvastatin 10 mg versus placebo. Adding the statin to the antihypertensive backbone reduced non-fatal MI and fatal coronary heart disease by 36% (HR 0.64; P=0.0005) [4]. While atorvastatin is not rosuvastatin, both are potent statins with similar LDL-lowering mechanisms. The ASCOT-LLA data provide the strongest trial-level support for combining a calcium channel blocker with a statin in hypertensive patients.

Who Specifically Benefits from Both Drugs

The overlap population is large. The CDC estimates that 47% of US adults have hypertension and that high cholesterol affects roughly 86 million adults [5]. The patient who needs both rosuvastatin and amlodipine might look like this:

• Age 55, male or postmenopausal female
• Blood pressure 145/88 mmHg on lifestyle modification alone
• LDL-C 118 mg/dL, 10-year ASCVD risk 9.2% by the Pooled Cohort Equations
• No contraindications to either drug class

In this profile, the 2019 ACC/AHA Primary Prevention Guideline recommends initiating a moderate-intensity statin (rosuvastatin 10 to 20 mg qualifies) and antihypertensive therapy. Amlodipine appears as a first-line antihypertensive option in the 2017 ACC/AHA High Blood Pressure Guideline for patients without compelling indications for another class [6].

The Fixed-Dose Combination Field

No FDA-approved fixed-dose tablet combines rosuvastatin with amlodipine. Caduet (amlodipine 2.5 to 10 mg / atorvastatin 10 to 80 mg) was approved in 2004 for patients who need both a statin and a calcium channel blocker, but rosuvastatin-specific combinations remain off the market in the US. Physicians who want a single-pill regimen using rosuvastatin must prescribe the two drugs separately or consider switching the statin component to atorvastatin if Caduet is preferred for adherence reasons.

HealthRX Decision Framework: Rosuvastatin + Amlodipine Co-Prescription

| Clinical Scenario | Rosuvastatin Needed? | Amlodipine Needed? | Notes | |---|---|---|---| | Elevated LDL-C only, normal BP | Yes | No | Add amlodipine only if BP rises | | Hypertension only, normal LDL-C | No | Yes | Statin threshold depends on ASCVD risk | | Both elevated LDL-C and hypertension, ASCVD risk >7.5% | Yes | Yes | Guideline-supported combination | | Stable angina with normal LDL-C | No | Yes | Amlodipine for angina prophylaxis | | Post-MI, mixed risk factors | Yes | Often yes | High-intensity statin preferred; CCB for BP or angina |

Drug Interaction Profile: Rosuvastatin and Amlodipine Together

The pharmacokinetic interaction between these two drugs is minimal. Rosuvastatin is metabolized primarily by CYP2C9 (minor) and is largely excreted unchanged in feces, with organic anion transporting polypeptides (OATP1B1 and OATP1B3) governing hepatic uptake. Amlodipine is metabolized by CYP3A4 and is not a significant inhibitor or inducer of the CYP enzymes relevant to rosuvastatin clearance [7].

Comparing Interaction Risk Across Statins

Not all statins are equal when paired with calcium channel blockers. Simvastatin and lovastatin are both CYP3A4 substrates. When combined with diltiazem or verapamil (both potent CYP3A4 inhibitors), plasma statin concentrations can rise substantially, increasing myopathy risk. The FDA actually limits simvastatin doses to 20 mg/day when co-prescribed with diltiazem or verapamil [8]. Amlodipine is a dihydropyridine and is not a clinically meaningful CYP3A4 inhibitor, so this concern does not apply even to simvastatin at standard doses. With rosuvastatin, the concern is essentially moot: the metabolic pathways do not overlap.

Monitoring Recommendations

When initiating rosuvastatin and amlodipine together:

1. Obtain a baseline lipid panel and hepatic function tests before starting rosuvastatin.
2. Recheck LDL-C at 4 to 12 weeks after rosuvastatin initiation or dose change.
3. Check blood pressure at 1 month after starting or up-titrating amlodipine.
4. Ask about lower-extremity edema at each visit (amlodipine-related, not rosuvastatin-related).
5. Creatine kinase (CK) levels are not routinely required but should be checked if the patient reports myalgias.

There is no pharmacokinetic rationale for dose-adjusting either drug based solely on co-prescription with the other.

Side Effects: Separating What Belongs to Which Drug

Patients and providers sometimes attribute amlodipine side effects to rosuvastatin, or vice versa. Getting this right affects adherence and clinical decision-making.

Rosuvastatin-Specific Adverse Effects

Myalgia is the most common reason patients discontinue statins. The SAMSON trial (N=60, crossover design) found that 90% of statin-attributed muscle symptoms occurred equally during placebo treatment, suggesting a large nocebo component [9]. True statin-induced myopathy (elevated CK greater than 10 times the upper limit of normal with symptoms) is rare, occurring in roughly 1 per 10,000 patient-years. Rosuvastatin 40 mg carries a small but real risk of new-onset diabetes, particularly in patients already at metabolic risk, as demonstrated in the JUPITER trial post-hoc analysis [2].

Transaminase elevations above three times the upper limit of normal occur in fewer than 1% of patients on rosuvastatin at standard doses [10].

Amlodipine-Specific Adverse Effects

Peripheral edema is the main dose-dependent adverse effect, affecting approximately 1.8% of patients on amlodipine 2.5 mg and rising to about 10.8% at 10 mg [11]. This edema results from precapillary vasodilation without simultaneous venodilation and is not a sign of heart failure. Reflex tachycardia is less common with amlodipine than with shorter-acting dihydropyridines. Gingival hyperplasia occurs rarely, predominantly with long-term use.

Patients who report ankle swelling on this combination should first confirm the swelling is ankle-predominant and position-dependent (suggesting amlodipine) rather than periorbital or diffuse (which would prompt different workup).

Should You Switch from Crestor to Amlodipine (or Vice Versa)?

Short answer: almost never.

Switching implies substituting one for the other, which requires both drugs to address the same clinical problem. They do not. A patient whose LDL-C is controlled on rosuvastatin 10 mg but who develops hypertension should have amlodipine added, not rosuvastatin stopped. A patient whose blood pressure is well-managed on amlodipine 5 mg but whose LDL-C rises to 142 mg/dL after dietary changes should have rosuvastatin started, not amlodipine discontinued.

Legitimate Reasons to Stop Rosuvastatin

• Confirmed statin-induced myopathy with CK elevation
• Severe hepatic impairment (Child-Pugh B or C)
• Pregnancy (Category X; absolute contraindication)
• Persistent intolerance after trying at least two different statins at reduced doses, confirmed by a statin re-challenge protocol

In these cases, the alternative is a different LDL-lowering therapy, such as ezetimibe, bempedoic acid, or a PCSK9 inhibitor, not amlodipine.

Legitimate Reasons to Stop Amlodipine

• Persistent symptomatic peripheral edema unresponsive to dose reduction
• Patient transition to a heart failure medication regimen where amlodipine is not preferred
• Clinically significant hypotension at lowest available dose

Again, the replacement would come from within the antihypertensive class or from an alternative class (ACE inhibitor, ARB, thiazide diuretic), not from rosuvastatin.

When Dose Adjustments Make Sense

Rosuvastatin dose can be escalated from 10 mg to 20 mg to 40 mg if LDL-C targets are not met. The maximum approved dose is 40 mg/day; the 80 mg dose was withdrawn from development due to an unfavorable muscle safety profile seen in the AURORA trial. Amlodipine dose can be titrated from 2.5 mg to 5 mg to 10 mg based on blood pressure response, with four to six weeks at each dose before re-assessment.

Neither drug's dosing is influenced by the presence of the other.

Evidence Summary: What the Major Trials Tell Us About Each Drug

Rosuvastatin: JUPITER and Beyond

JUPITER enrolled 17,802 apparently healthy adults with LDL-C below 130 mg/dL but hsCRP at or above 2.0 mg/L. Rosuvastatin 20 mg reduced LDL-C by 50% and hsCRP by 37%. The primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) was reduced by 44% (HR 0.56; P<0.00001) over a median follow-up of 1.9 years [2]. The trial was stopped early by the independent data safety monitoring board for overwhelming efficacy.

The METEOR trial (N=984) showed rosuvastatin 40 mg slowed progression of carotid intima-media thickness by 0.0014 mm/year versus progression of 0.0131 mm/year with placebo (P<0.001) [12], providing imaging-level mechanistic support for the clinical JUPITER result.

Amlodipine: ASCOT-BPLA and CAMELOT

ASCOT-BPLA compared an amlodipine-based regimen (with perindopril added as needed) to an atenolol-based regimen in 19,257 hypertensive patients. After a median follow-up of 5.5 years, the amlodipine arm reduced total cardiovascular events and procedures by 16% (P<0.0001), stroke by 23% (P=0.0003), and cardiovascular mortality by 24% (P=0.001) [3]. This trial established amlodipine-based therapy as superior to beta-blocker-based therapy for broad cardiovascular event prevention in hypertensive patients without heart failure.

CAMELOT (N=1,991) randomized patients with coronary artery disease and normal or mildly elevated blood pressure to amlodipine 10 mg, enalapril 20 mg, or placebo. Amlodipine reduced the primary endpoint of adverse cardiovascular events by 31% versus placebo (P=0.003) [13], and intravascular ultrasound substudy data showed a trend toward less atheroma progression with amlodipine.

Taken together, these trials confirm that both drugs independently reduce hard cardiovascular endpoints, and that their mechanisms are additive rather than overlapping.

Special Populations: Dosing Considerations That Change the Calculus

Elderly Patients (Age 75 and Older)

Start amlodipine at 2.5 mg in elderly patients to reduce hypotension risk. Rosuvastatin should be initiated at 5 mg in patients with a creatine clearance below 30 mL/min, per FDA labeling, due to increased plasma concentrations from reduced renal clearance [14].

Asian Patients

Rosuvastatin plasma concentrations are approximately two-fold higher in patients of Asian ancestry due to OATP1B1 polymorphisms and body composition differences. The FDA recommends a starting dose of 5 mg and a maximum dose of 20 mg in Asian patients [14]. Amlodipine pharmacokinetics are not meaningfully altered by Asian ancestry.

Patients with Chronic Kidney Disease

Amlodipine requires no dose adjustment in CKD. Rosuvastatin at doses above 10 mg should be used cautiously in patients with GFR below 30 mL/min, and the 40 mg dose is contraindicated in severe renal impairment per FDA labeling [14].

Patients with Diabetes

JUPITER data confirmed a 25% relative increase in physician-reported diabetes with rosuvastatin versus placebo. This risk is consistent across the statin class and is generally outweighed by cardiovascular benefit in patients meeting statin criteria. The American Diabetes Association's Standards of Care in Diabetes recommends that patients with diabetes aged 40 to 75 with additional ASCVD risk factors receive a moderate-to-high-intensity statin regardless of baseline LDL-C [15]. Amlodipine has a neutral metabolic profile and does not impair glucose tolerance.

Practical Prescribing: How to Initiate and Monitor the Combination

Starting both drugs on the same day is common in newly diagnosed patients with hypertension plus dyslipidemia. A few practical points:

• Both drugs are dosed once daily and can be taken at any time. Neither requires food.
• Rosuvastatin is typically taken in the evening (aligning with peak hepatic cholesterol synthesis overnight), though morning dosing produces similar LDL lowering given the drug's 19-hour half-life.
• Amlodipine's long half-life (35 to 50 hours) makes it forgiving of missed doses.
• Grapefruit juice does not meaningfully affect rosuvastatin or amlodipine, unlike simvastatin or atorvastatin.
• Coadministration with antacids (aluminum/magnesium hydroxide combinations) can reduce rosuvastatin AUC by approximately 54%; separate dosing by at least two hours [14].

A 90-day supply of generic rosuvastatin costs under $15 at most US pharmacy chains. Generic amlodipine is similarly inexpensive. The cost barrier to dual therapy is low.